{"DataElement":{"publicId":"4459198","version":"1","preferredName":"Theradex Treatment Cohort Study Type","preferredDefinition":"The response that represents the information pertaining to studies in which subsets of a defined population are identified.","longName":"TDX_TX_CO_SDY_TP","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"2497526","version":"1","preferredName":"Treatment Cohort Study","preferredDefinition":"Information pertaining to studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.","longName":"TX_COHORT_STDY","context":"DCP","contextVersion":"1","ObjectClass":{"publicId":"2416951","version":"1","preferredName":"Therapy","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C15368","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"02DBEE3F-243E-103A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-12","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-10-12","modifiedBy":"ONEDATA","dateModified":"2005-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2497524","version":"1","preferredName":"Cohort Study","preferredDefinition":"Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.","longName":"C15208","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cohort Study","conceptCode":"C15208","definition":"A research study that compares a particular outcome (such as lung cancer) in groups of individuals who are alike in many ways but differ by a certain characteristic (for example, female nurses who smoke compared with those who do not smoke).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"191BBE49-FC9E-4C77-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-07-21","modifiedBy":"ONEDATA","dateModified":"2006-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"191BBE49-FCAF-4C77-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-07-21","modifiedBy":"SOKKERL","dateModified":"2017-05-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4459170","version":"1","preferredName":"Theradex Cohort Type","preferredDefinition":"A group of individuals, identified by a common characteristic._Something distinguishable as an identifiable class based on common qualities.","longName":"4459170v1.0","context":"Theradex","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"250","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"D DL+2","valueDescription":"D DL+2: Cycle=28 days, Severe hepatic dysfunction (bilirubin greater than 3x ULN but less than or equal to 10x ULN and any AST), Trametinib: 2.0 mg PO QD","ValueMeaning":{"publicId":"4459359","version":"1","preferredName":"D DL+2: Cycle=28 days, Severe hepatic dysfunction (bilirubin greater than 3x ULN but less than or equal to 10x ULN and any AST), Trametinib: 2.0 mg PO QD","longName":"4459359","preferredDefinition":"D DL+2: Cycle=28 days, Severe hepatic dysfunction (bilirubin greater than 3x ULN but less than or equal to 10x ULN and any AST), Trametinib: 2.0 mg PO QD","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01266F74-F19E-83B3-E050-BB89AD430519","latestVersionIndicator":"Yes","beginDate":"2014-08-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-08-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"01266F74-F1B7-83B3-E050-BB89AD430519","beginDate":"2014-08-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-08-21","modifiedBy":"HARTLEYG","dateModified":"2014-08-22","deletedIndicator":"No"},{"value":"D DL+1","valueDescription":"D DL+1: Cycle=28 days, Severe hepatic dysfunction (bilirubin greater than 3x ULN but less than or equal to 10x ULN and any AST), Trametinib: 1.5 mg PO QD","ValueMeaning":{"publicId":"4459360","version":"1","preferredName":"D DL+1: Cycle=28 days, Severe hepatic dysfunction (bilirubin greater than 3x ULN but less than or equal to 10x ULN and any AST), Trametinib: 1.5 mg PO QD","longName":"4459360","preferredDefinition":"D DL+1: Cycle=28 days, Severe hepatic dysfunction (bilirubin greater than 3x ULN but less than or equal to 10x ULN and any AST), Trametinib: 1.5 mg PO QD","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01266F74-F1C1-83B3-E050-BB89AD430519","latestVersionIndicator":"Yes","beginDate":"2014-08-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-08-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"01266F74-F1DA-83B3-E050-BB89AD430519","beginDate":"2014-08-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-08-21","modifiedBy":"HARTLEYG","dateModified":"2014-08-22","deletedIndicator":"No"},{"value":"C DL+1","valueDescription":"C DL+1: Cycle=28 days, Moderate hepatic dysfunction (bilirubin greater than 1.5 x ULN but less than or equal to 3x ULN and any AST), Trametinib: 2.0 mg PO QD","ValueMeaning":{"publicId":"4459363","version":"1","preferredName":"C DL+1: Cycle=28 days, Moderate hepatic dysfunction (bilirubin greater than 1.5 x ULN but less than or equal to 3x ULN and any AST), Trametinib: 2.0 mg PO QD","longName":"4459363","preferredDefinition":"C DL+1: Cycle=28 days, Moderate hepatic dysfunction (bilirubin greater than 1.5 x ULN but less than or equal to 3x ULN and any AST), Trametinib: 2.0 mg PO QD","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01266F74-F22A-83B3-E050-BB89AD430519","latestVersionIndicator":"Yes","beginDate":"2014-08-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-08-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"01266F74-F243-83B3-E050-BB89AD430519","beginDate":"2014-08-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-08-21","modifiedBy":"HARTLEYG","dateModified":"2014-08-22","deletedIndicator":"No"},{"value":"D DL1","valueDescription":"D DL1: Cycle=28 days, Severe hepatic dysfunction (bilirubin greater than 3x ULN but less than or equal to 10x ULN and any AST), Trametinib: 1.0 mg PO QD","ValueMeaning":{"publicId":"4459361","version":"1","preferredName":"D DL1: Cycle=28 days, Severe hepatic dysfunction (bilirubin greater than 3x ULN but less than or equal to 10x ULN and any AST), Trametinib: 1.0 mg PO QD","longName":"4459361","preferredDefinition":"D DL1: Cycle=28 days, Severe hepatic dysfunction (bilirubin greater than 3x ULN but less than or equal to 10x ULN and any AST), Trametinib: 1.0 mg PO QD","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01266F74-F1E4-83B3-E050-BB89AD430519","latestVersionIndicator":"Yes","beginDate":"2014-08-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-08-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"01266F74-F1FD-83B3-E050-BB89AD430519","beginDate":"2014-08-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-08-21","modifiedBy":"HARTLEYG","dateModified":"2014-08-22","deletedIndicator":"No"},{"value":"D DL-1","valueDescription":"D DL-1: Cycle=28 days, Severe hepatic dysfunction (bilirubin greater than 3x ULN but less than or equal to 10x ULN and any AST), Trametinib: 0.5 mg PO QD","ValueMeaning":{"publicId":"4459362","version":"1","preferredName":"D DL-1: Cycle=28 days, Severe hepatic dysfunction (bilirubin greater than 3x ULN but less than or equal to 10x ULN and any AST), Trametinib: 0.5 mg PO QD","longName":"4459362","preferredDefinition":"D DL-1: Cycle=28 days, Severe hepatic dysfunction (bilirubin greater than 3x ULN but less than or equal to 10x ULN and any AST), Trametinib: 0.5 mg PO QD","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01266F74-F207-83B3-E050-BB89AD430519","latestVersionIndicator":"Yes","beginDate":"2014-08-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-08-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"01266F74-F220-83B3-E050-BB89AD430519","beginDate":"2014-08-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-08-21","modifiedBy":"HARTLEYG","dateModified":"2014-08-22","deletedIndicator":"No"},{"value":"C DL1","valueDescription":"C DL1: Cycle=28 days, Moderate hepatic dysfunction (bilirubin greater than 1.5 x ULN but less than or equal to 3x ULN and any AST), Trametinib: 1.5 mg PO QD","ValueMeaning":{"publicId":"4459364","version":"1","preferredName":"C DL1: Cycle=28 days, Moderate hepatic dysfunction (bilirubin greater than 1.5 x ULN but less than or equal to 3x ULN and any AST), Trametinib: 1.5 mg PO QD","longName":"4459364","preferredDefinition":"C DL1: Cycle=28 days, Moderate hepatic dysfunction (bilirubin greater than 1.5 x ULN but less than or equal to 3x ULN and any AST), Trametinib: 1.5 mg PO QD","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01266F74-F24D-83B3-E050-BB89AD430519","latestVersionIndicator":"Yes","beginDate":"2014-08-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-08-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"01266F74-F266-83B3-E050-BB89AD430519","beginDate":"2014-08-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-08-21","modifiedBy":"HARTLEYG","dateModified":"2014-08-22","deletedIndicator":"No"},{"value":"C DL-1","valueDescription":"C DL-1: Cycle=28 days, Moderate hepatic dysfunction (bilirubin greater than 1.5 x ULN but less than or equal to 3x ULN and any AST), Trametinib: 1.0 mg PO QD","ValueMeaning":{"publicId":"4459365","version":"1","preferredName":"C DL-1: Cycle=28 days, Moderate hepatic dysfunction (bilirubin greater than 1.5 x ULN but less than or equal to 3x ULN and any AST), Trametinib: 1.0 mg PO QD","longName":"4459365","preferredDefinition":"C DL-1: Cycle=28 days, Moderate hepatic dysfunction (bilirubin greater than 1.5 x ULN but less than or equal to 3x ULN and any AST), Trametinib: 1.0 mg PO QD","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01266F74-F270-83B3-E050-BB89AD430519","latestVersionIndicator":"Yes","beginDate":"2014-08-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-08-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"01266F74-F289-83B3-E050-BB89AD430519","beginDate":"2014-08-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-08-21","modifiedBy":"HARTLEYG","dateModified":"2014-08-22","deletedIndicator":"No"},{"value":"C DL-2","valueDescription":"C DL-2: Cycle=28 days, Moderate hepatic dysfunction (bilirubin greater than 1.5 x ULN but less than or equal to 3x ULN and any AST), Trametinib: 0.5 mg PO QD","ValueMeaning":{"publicId":"4459366","version":"1","preferredName":"C DL-2: Cycle=28 days, Moderate hepatic dysfunction (bilirubin greater than 1.5 x ULN but less than or equal to 3x ULN and any AST), Trametinib: 0.5 mg PO QD","longName":"4459366","preferredDefinition":"C DL-2: Cycle=28 days, Moderate hepatic dysfunction (bilirubin greater than 1.5 x ULN but less than or equal to 3x ULN and any AST), Trametinib: 0.5 mg PO QD","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01266F74-F293-83B3-E050-BB89AD430519","latestVersionIndicator":"Yes","beginDate":"2014-08-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-08-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"01266F74-F2AC-83B3-E050-BB89AD430519","beginDate":"2014-08-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-08-21","modifiedBy":"HARTLEYG","dateModified":"2014-08-22","deletedIndicator":"No"},{"value":"B DL1","valueDescription":"B DL1: Cycle=28 days, Mild hepatic dysfunction (B1: bilirubin less than or equal to ULN and AST greater than ULN, and B2: Bilirubin greater than ULN but less than or equal to 1.5x ULN and any AST), Trametinib: 2.0 mg PO QD","ValueMeaning":{"publicId":"4459367","version":"1","preferredName":"B DL1: Cycle=28 days, Mild hepatic dysfunction (B1: bilirubin less than or equal to ULN and AST greater than ULN, and B2: Bilirubin greater than ULN but less than or equal to 1.5x ULN and any AST), Trametinib: 2.0 mg PO QD","longName":"4459367","preferredDefinition":"B DL1: Cycle=28 days, Mild hepatic dysfunction (B1: bilirubin less than or equal to ULN and AST greater than ULN, and B2: Bilirubin greater than ULN but less than or equal to 1.5x ULN and any AST), Trametinib: 2.0 mg PO QD","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01266F74-F2B6-83B3-E050-BB89AD430519","latestVersionIndicator":"Yes","beginDate":"2014-08-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-08-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"01266F74-F2CF-83B3-E050-BB89AD430519","beginDate":"2014-08-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-08-21","modifiedBy":"HARTLEYG","dateModified":"2014-08-22","deletedIndicator":"No"},{"value":"B DL-1","valueDescription":"B DL-1: Cycle=28 days, Mild hepatic dysfunction (B1: bilirubin less than or equal to ULN and AST greater than ULN, and B2: Bilirubin greater than ULN but less than or equal to 1.5x ULN and any AST), Trametinib: 1.5 mg PO QD","ValueMeaning":{"publicId":"4459368","version":"1","preferredName":"B DL-1: Cycle=28 days, Mild hepatic dysfunction (B1: bilirubin less than or equal to ULN and AST greater than ULN, and B2: Bilirubin greater than ULN but less than or equal to 1.5x ULN and any AST), Trametinib: 1.5 mg PO QD","longName":"4459368","preferredDefinition":"B DL-1: Cycle=28 days, Mild hepatic dysfunction (B1: bilirubin less than or equal to ULN and AST greater than ULN, and B2: Bilirubin greater than ULN but less than or equal to 1.5x ULN and any AST), Trametinib: 1.5 mg PO QD","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01266F74-F2D9-83B3-E050-BB89AD430519","latestVersionIndicator":"Yes","beginDate":"2014-08-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-08-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"01266F74-F2F2-83B3-E050-BB89AD430519","beginDate":"2014-08-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-08-21","modifiedBy":"HARTLEYG","dateModified":"2014-08-22","deletedIndicator":"No"},{"value":"B DL-2","valueDescription":"B DL-2: Cycle=28 days, Mild hepatic dysfunction (B1: bilirubin less than or equal to ULN and AST greater than ULN, and B2: Bilirubin greater than ULN but less than or equal to 1.5x ULN and any AST), Trametinib: 1.0 mg PO QD","ValueMeaning":{"publicId":"4459369","version":"1","preferredName":"B DL-2: Cycle=28 days, Mild hepatic dysfunction (B1: bilirubin less than or equal to ULN and AST greater than ULN, and B2: Bilirubin greater than ULN but less than or equal to 1.5x ULN and any AST), Trametinib: 1.0 mg PO QD","longName":"4459369","preferredDefinition":"B DL-2: Cycle=28 days, Mild hepatic dysfunction (B1: bilirubin less than or equal to ULN and AST greater than ULN, and B2: Bilirubin greater than ULN but less than or equal to 1.5x ULN and any AST), Trametinib: 1.0 mg PO QD","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01266F74-F2FC-83B3-E050-BB89AD430519","latestVersionIndicator":"Yes","beginDate":"2014-08-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-08-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"01266F74-F315-83B3-E050-BB89AD430519","beginDate":"2014-08-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-08-21","modifiedBy":"HARTLEYG","dateModified":"2014-08-22","deletedIndicator":"No"},{"value":"A DL1","valueDescription":"A DL1: Cycle=28 days, Normal hepatic function (Bilirubin less than or equal to ULN, AST less than or equal to ULN), Trametinib: 2.0 mg PO QD","ValueMeaning":{"publicId":"4459182","version":"1","preferredName":"A DL1: Cycle=28 days, Normal hepatic function (Bilirubin less than or equal to ULN, AST less than or equal to ULN), Trametinib: 2.0 mg PO QD","longName":"4459182","preferredDefinition":"A DL1: Cycle=28 days, Normal hepatic function (Bilirubin less than or equal to ULN, AST less than or equal to ULN), Trametinib: 2.0 mg PO QD","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0116AD40-5108-D42D-E050-BB89AD43140D","latestVersionIndicator":"Yes","beginDate":"2014-08-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"01266F74-F329-83B3-E050-BB89AD430519","beginDate":"2014-08-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-08-21","modifiedBy":"HARTLEYG","dateModified":"2014-08-22","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435021","version":"1","preferredName":"Diagnostic or Prognostic Factor","preferredDefinition":"Top level term which includes Biological Markers, Risk Factors, and Prognostic Factors.","longName":"C20047","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741C99A-9B70-231B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"4459169","version":"1","preferredName":"Cohort Type","preferredDefinition":"A group of individuals, identified by a common characteristic.:Something distinguishable as an identifiable class based on common qualities.","longName":"C61512:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cohort","conceptCode":"C61512","definition":"A group of individuals, identified by a common characteristic.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0116AD40-4F60-D42D-E050-BB89AD43140D","latestVersionIndicator":"Yes","beginDate":"2014-08-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-20","modifiedBy":"ONEDATA","dateModified":"2014-08-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0116AD40-4F71-D42D-E050-BB89AD43140D","latestVersionIndicator":"Yes","beginDate":"2014-08-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-20","modifiedBy":"HARTLEYG","dateModified":"2014-08-22","changeDescription":"9591_Theradex_08-20-14_GHD","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876594","version":"1","longName":"Theradex","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876603","version":"1","longName":"Theradex - CTMS 3.14","context":"Theradex"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Please select the cohort","type":"Preferred Question Text","description":"Please select the cohort","url":null,"context":"Theradex"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0116AD40-5131-D42D-E050-BB89AD43140D","latestVersionIndicator":"Yes","beginDate":"2014-08-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-20","modifiedBy":"HARTLEYG","dateModified":"2014-08-20","changeDescription":"9591_Theradex_08-20-14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}